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Individuals with Birt–Hogg–Dubé syndrome (BHDS) may develop fibrofolliculomas, pneumothorax and/or renal cell carcinoma
(RCC). Currently, all patients with pathogenic FLCN variants are recommended to have renal surveillance. It has however been
suggested that some FLCN variants only cause pneumothorax, which would make surveillance unnecessary in certain cases. This
review assesses this possibility. We provide an up-to-date analysis of clinical and genetic features of BHDS. The PUBMED database
was systematically searched to find all articles describing patients with pathogenic FLCN variants. The relevant clinical and genetic
features of these patients were recorded and analysed. The prevalence of pneumothorax, pulmonary cysts, RCC and characteristic
skin lesions in BHDS were 50.9% (n= 1038), 91.9% (n= 720), 22.5% (n= 929) and 47.9% (n= 989), respectively. There was a higher
prevalence of pneumothoraces (p < 0.0001) but lower prevalence of dermatological findings (p < 0.0001) in patients from East Asia
compared to North America or Europe. Of the 194 pathogenic FLCN variants, 76 could be defined as ‘pneumothorax-only’.
Pneumothorax only pathogenic variants (POPVs) were distributed throughout the gene, and there were no statistical differences in
variant type. The majority of POPVs (65/76) affected no more than three individuals. Individuals with ‘POPVs’ also tended to be
younger (45 vs. 47 years, p < 0.05). Many apparent POPVs in the literature could result from variable expressivity, age-related
penetrance and other confounding factors. We therefore recommend that all individuals found to carry a pathogenic FLCN variant
be enroled in lifelong surveillance for RCC.
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INTRODUCTION
Pneumothorax indicates air in the pleural space. When this occurs
without trauma or obvious lung pathology, the patient is said to
suffer from a primary spontaneous pneumothorax. In 10% of
cases, there is a family history of pneumothorax and subsequent
investigation can uncover a variety of syndromic causes [1].
Birt–Hogg–Dubé syndrome (BHDS) is the most common genetic
disorder diagnosed in individuals with familial pneumothorax [1].
It is caused by variants in the FLCN gene, which encodes the
protein folliculin. FLCN comprises 14 exons and many pathogenic
variants have been identified. Although these span the entire
length of the coding sequence, several mutational hotspots exist,
notably a polycytosine tract in exon 11 where insertion/deletion
variants accounts for nearly 50% of all pathogenic FLCN variants in
some cohorts [2].
FLCN variants are associated with the development of basal
pulmonary cysts that are prone to rupture causing pneumothorax.
More importantly, patients with BHDS are at increased risk of
developing renal cancer (lifetime risk 25–30%). Since renal
malignancy can often be cured by early surgery, annual
surveillance for small malignant renal tumours has been
recommended in individuals with BHDS [3]. In addition to
individuals diagnosed with BHDS, pathogenic FLCN variants have
also been described in individuals with familial pneumothorax but
no other features of BHDS [4–6]. In some cases, it has been
suggested that specific FLCN variants could result in a
pneumothorax-only phenotype [4–6]. Most FLCN variants are
truncating and will therefore cause loss of function. By contrast,
variants that retain partial function, for example some missense
variants, might lead to a milder phenotype. Indeed, truncating
variants in the last exon and within the last 50 nucleotides of the
penultimate gene have previously shown to escape nonsense-
mediated decay [7].
If such genotype–phenotype correlation really exists, individuals
with ‘pneumothorax-only’ pathogenic variants (POPVs) could, in
theory, be spared lifelong renal surveillance, allowing medical
resources to be better targeted and reducing the risk of screening-
associated anxiety. To evaluate the implications of putative POPVs
in FLCN for clinical practice, we performed a systematic review of
genotype–phenotype relationships in published cases of this rare
inherited disease. In particular, we investigated whether there was
a difference in certain characteristics between putative POPVs and
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non-POPVs (variant type, location, age of patients, number of
patients with that variant) to determine whether the presence of
POPVs has biological plausibility or is likely an artefact.
METHODS
Literature review
Following the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines, we ensured that all
included studies had obtained ethical approval. The PUBMED
database was searched from 1st July 1974 to 1st March 2021 for
English language articles using the keywords ‘Birt–-Hogg–-Dubé’
and ‘Hornstein–Knickenberg’, the latter being an alternate name
for BHDS. The references list of the articles thus identified were
then searched to identify additional relevant papers. Only articles
reporting patients with genetically confirmed pathogenic FLCN
variants were included. FLCN variants deemed not to be at least
‘likely pathogenic’ by the LOVD3 database or ACMG guidelines
were excluded. Case reports and case series were included
because they often contained novel variants that were not
identified in larger cross-sectional studies. We also updated the
European BHD Mutation Database (LOVD3) to contain all data
described (both phenotypic and genotypic) [8] and papers were
referenced in this database accordingly.
Data extraction
The anonymised patient details from the 158 articles were
recorded on an Excel spreadsheet. Where available the following
were noted: patient’s age, sex, phenotypes (pneumothorax, cyst,
skin changes, RCC), age when each phenotype was first noted,
FLCN variant type, country where diagnosis was made and family
history. This information was extracted from each paper. Not all
papers reported the presence or absence of each phenotype
resulting in missing data. In these situations, the particular
phenotype is recorded as ‘data not available’. Available data are
presented as a proportion with denominators representing
individuals for whom relevant data were available. When details
of individuals matched in two publications, the publications were
scrutinised for evidence of potential duplication. To minimise
selection bias, care was taken when recording the presence or
absence of phenotypes. The presence or absence of RCC and lung
cysts was recorded only if an abdominal ultrasound or CT were
recorded as performed. Presence or absence of dermatological
findings was recorded only if dermatological examination was
explicitly noted. The speciality of the studies’ authors was noted to
analyse potential bias between studies.
We wished to test for the existence of FLCN variants associated
with pneumothorax but not renal cell carcinomas. We were less
concerned to subdivide further these by skin pathology, because
only renal cancer necessitates surveillance imaging. We therefore
chose not to include skin phenotypes in our definition of POPV as
a variant reported to cause pneumothorax but not renal
carcinoma.
Statistical analysis
Individuals were often not independent from each other as they
belonged to the same family and therefore statistical models that
accounted for this were used. Differences between mutually
exclusive classes were examined by a mixed effects logistic
regression model with a random-effects term for family. A linear
mixed model with a random-effects term for family was used to
compare two groups when the dependent variable was not
normally distributed.
RESULTS
We identified 666 papers on BHDS. Of these, 158 met the inclusion
criteria by reporting genetically confirmed pathogenic FLCN
variants (Fig. 1). A total of 1059 individuals from 575 families
were thus identified. Patients ranged in age from 2 to 92 years
(median 46 years); 45.7% were male, and 68.8% had a confirmed
family history of BHDS. Geographically, 32.7% were diagnosed in
North America, 31.7% in Europe and 33.3% in E-Asia (Japan, South
Korea, China and Taiwan).
Clinical features
Overall, 50.9% (528/1038) of reported individuals had experienced
at least one pneumothorax (Table 1) [2, 4–6, 8–41]. Of these, 66.7%
(220/330) had recurrent pneumothoraces. There was no lateralisa-
tion of the pneumothoraces (46.4% left, 53.6% right). The median
age at first pneumothorax was 34 years (range 10–78 years; n=
257), while the median age of individuals at the time of their case
report was 46 years (range 14–92 years; n= 342). Of the patients
who underwent thoracic CT imaging, 92.1% (662/720) had
reported lung cysts. Of these patients, 63.7% had a pneumothorax
[2, 4–6, 8–18, 21–28, 30, 31, 34–41].
Of the 989 patients with recorded dermatological examinations,
47.9% had lesions consistent with BHDS [2, 4–6, 8–18, 20–41].
Most had fibrofolliculomas (90.5%; 429/474), 8.8% (42/474) had
trichodiscomas and 4.0% (19/474) had perifollicular adenomas.
The median age at which skin changes were first noted was 38
years (range 20–65 years; n= 44), while the median age of these
individuals at the time of their case report was 51 years (range
22–92 years; n= 213).
Of the 929 patients who underwent imaging of the abdomen,
22.5% had malignant renal tumours [2, 6, 8–18, 20–29, 31–41]. In
52.5% (62/118), the tumour was unifocal and did not recur after
excision. A variety of histological subtypes were reported:
chromophobe 32.8% (63/192), hybrid oncocytoma-chromophobe
24.5% (47/192), clear cell 11.5% (22/192), oncocytomas 9.9% (19/
192), hybrid clear cell-chromophobe 7.3% (14/192), papillary 5.2%
(10/192) and the remaining patients had either a hybrid
oncocytoma-clear cell or a hybrid papillary-clear cell tumour. The
median age at first diagnosis of renal cell carcinoma was 47 years
(range 14–83 years; n= 108). Their median age at the time of case
report was 52 years (14–92 years; n= 121).
Differences were apparent in the phenotypes reported in
geographical regions. The frequency of pulmonary cysts in East
Asia was significantly higher (96.8%; 302/312) than North America
(89.0%; 218/245) or Europe (88.2%; 134/152) (p < 0.0001)
[2, 4–6, 8–18, 20–30, 34–41]. Similarly, a higher proportion of
pneumothorax was seen in East Asian reports (73.9%; 249/337)
compared with North America (35.1%, 120/342) or Europe (44.6%,
150/336) (p < 0.0001). By contrast, a slightly higher proportion of
renal cancer was observed in European reports (27.1%, 83/306)
than in either North American (23.9%, 75/314) or East Asian
individuals (16.4%, 47/286) (p < 0.05). More strikingly, the propor-
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Fig. 1 Study selection PRISMA diagram. Articles published
between 1st July 1974 and 1st March 2021 were identified in
PUBMED and screened as identified.
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66/320) than in European (50.3%, 153/304) or North American
cases (73.4%, 251/342) (p < 0.0001).
Of the individuals where the data were available, the commonest
presentation was a positive family history of the disorder (44.0% of
individuals, 438/995) [2, 4–6, 8–18, 20–29, 31–41]. Skin findings
were the presenting feature in 17.8% (177/995) of diagnoses,
followed by pneumothorax in 19.6% (195/995) and renal cancer in
7.5% (75/995) of cases. The remainder could not be linked to a
single feature or were the result of incidental detection of
pulmonary cysts after CT scanning. Of note, a longer latency to
diagnosis was observed when pneumothorax was the first clinical
feature (median time to diagnosis 6 years; n= 138) compared with
0 years for both RCC (n= 13) and skin changes (n= 36).
Genetic features
A total of 194 pathogenic variants were identified from the
literature [2, 4–6, 8–18, 20–42]. These comprised 132 nonsense
and frameshift variants, 31 intronic variants, 11 missense variants/
in-frame deletions, 13 large deletions/duplications and 7 variants
affecting the initiation of transcription (Fig. 2A and Supplementary
Table 1). Eleven variants had no associated patient details and so
were excluded from subsequent analyses.
It has been suggested that certain FLCN variants lead to a forme
fruste of BHDS with pneumothoraces but no renal cancers [4, 5].
Since the existence of ‘pneumothorax-only’ FLCN variants would
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Fig. 2 Pathogenic FLCN variants. A Missense/in-frame variants in
red, frameshifts in blue, nonsense variants in light green, large
deletions/duplications in orange. Bars are proportional to numbers
of affected individuals, for mutational hotspots the number of
individuals is given above each bar. ‘Pneumothorax-only’ patho-
genic variants (POPV) shown above exons, all other variants shown
below. B Histogram of individuals affected by POPV (red), all other
variants (purple). C Ages of individuals reported to carry POPV (red)
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examined these in more detail. Of the 183 variants, there were 76
‘pneumothorax-only’ variants, 24 also had skin changes (Fig. 2A).
POPVs were distributed throughout the gene (Fig. 2A) and no
association was found with variant type (p= 0.78). We hypothe-
sised that at least some FLCN variants might erroneously appear as
POPVs if detected in younger or smaller families with less chance
of having manifested renal carcinomas and were not adequately
followed-up (given that the median age at first pneumothorax was
34 years and median age at RCC was 47 years). Indeed, we
observed that a majority of putative POPVs (85.5%, 65/76) affected
no more that three individuals (Fig. 2B, C). Furthermore, the
median age of individuals with POPVs was significantly lower than
those with non-pneumothorax-only variants (45 vs. 47 years, p <
0.01). Importantly, there were less data on elderly members (70
years or over) in families with reportedly ‘pneumothorax-only’
variants (Fig. 2C).
Of 991 individuals studied in this review, 10 were diagnosed
before the age of 18 (range: 2 to 17) and a further 7 were
diagnosed between the ages of 18 and 20 [8, 12, 16, 18, 33–40]. Of
the ten patients diagnosed before the age of 18, six were
asymptomatic (five diagnosed through family screening and one
through a mutation analysis following a diagnosis of leiomyo-
sarcoma), three presented with pneumothoraces and one
presented with renal cell carcinoma. Overall, there were 14
patients with a FLCN variant, who had their first pneumothorax
before the age of 20 [8, 12, 13, 18, 31, 32, 34–36, 41]. There was
one case of renal cell carcinoma [33] and no cases of
pathognomonic skin lesions. The youngest ages of presentation
for pneumothorax and renal cell carcinoma were 10 and 14,
respectively [33, 36].
DISCUSSION
From the literature, we identified 1059 individuals with patho-
genic FLCN variants across 575 families. Although it is known that
such FLCN variants increase the risk of pneumothorax by up to 50-
fold [43], the true proportion of pneumothoraces in BHDS remains
unclear. We found that 50.9% of reported individuals with FLCN
variants had suffered at least one pneumothorax, which is
considerably higher than the 30% typically quoted [43]. This
difference may reflect reporting bias in the literature compared to
large cross-sectional studies. It is noteworthy that many indivi-
duals (44.0%) were identified through family tracing and so many
were young and yet to develop complications.
A variety of genetic disorders can present to the respiratory
physician as pneumothorax. The diagnoses that can subsequently
be made can lead to life-extending treatments, not for the
pneumothorax but for other features of the genetic disorder. In
the case of BHDS, although patients often present with
pneumothorax, they are also at risk for developing potentially
fatal renal cancer years later. Annual screening is currently
recommended [3], but several reports of POPVs have brought
into question the necessity for screening all patients with FLCN
variants [4, 5].
As well as missense mutations, we looked at truncating variants
in the last exon and the last 50 nucleotides of the penultimate
exon, in particular, as they have previously shown to escape
nonsense-mediated decay [7]. Such an event would result in a
carboxyterminally truncated folliculin protein that might retain
partial function and so generate an attenuated phenotype
compared with other variants that produce little or no protein.
Indeed, Park et al. [30] reported a novel FLCN c.1489_1490delTG
pathogenic variant that escaped nonsense-mediated mRNA
decay. The variant was within the last 50 base pairs of exon 13
and the proband had presented with recurrent primary sponta-
neous pneumothorax but no renal cell carcinoma. This observa-
tion would be consistent with the hypothesis that exon 14 variants
might have a milder phenotype. In this study, however, we found
no association between variant type (missense or truncating
mutations in the last exon/last 50 nucleotides of exon 13)
and POPVs.
Overall, although ‘apparent POPVs’ could represent true
‘pneumothorax-only variants’, it seems more likely that they are
artefacts for the following reasons: (i) on average each apparent
POPV is carried by fewer individuals than non-POPV variants, (ii)
no unequivocal clustering of such variants was apparent in the
FLCN gene or folliculin protein domains and (iii) POPVs were more
likely to be found in younger patients who have a lower
probability of manifesting age-related renal tumours. We therefore
recommend that all patients with BHDS and or pathogenic
variants in the FLCN gene are offered renal surveillance.
Our review supports reports that pulmonary manifestations of
BHDS appear more frequently in East Asian populations [13].
Conversely, renal cell cancer and dermatological features seem
less common in East Asians. It is unclear if these findings reflect
differences in genetic or environmental factors, or differences in
diagnostic pathways. It is plausible that unidentified environ-
mental factors might play a role. For example, sun exposure is
thought to predispose individuals with tuberous sclerosis to
angiofibromata [44]. It is not clear, however, if similar factors affect
the development of fibrofolliculomas. On the other hand, most
skin examinations reported in the East Asian papers were
performed by respiratory physicians, while it is known that
dermatologists are threefold (23.3% vs. 73.9%) more likely to
identify skin lesions in patients with BHDS [31]. Moreover, there
are fewer follicular units in individuals from East Asia compared to
Caucasians [45], which might lead to fewer fibrofolliculomas being
present and so more likely to be overlooked.
Pneumothoraces were recurrent in 66.7% of individuals with a
FLCN variant who previously presented with a pneumothorax. This
is higher than the 30% reported for large series of spontaneous
pneumothoraces [46]. It remains possible that thorough investiga-
tion of pneumothoraces and consequent diagnosis of BHDS were
more likely in patients with recurrent pneumothoraces. Prospec-
tive long-term follow up of individuals identified by family tracing
is necessary to determine the true recurrence rate. Renal cell
carcinoma, the most sinister pathology in BHDS, had a prevalence
of 22.5% consistent with previous estimates of 12–34% [32]. In
contrast to pneumothorax, which had a median age of diagnosis
of 34 years, renal cancer was a later complication with a median
age at diagnosis of 47 years, although the range was large.
Skin changes consistent with BHDS were found in 47.9% of
patients, which is considerably lower than the 85% suggested in
previous reports [43]. This might reflect the increasing number of
East Asian case reports, which report much lower proportions of
positive skin findings. The median age at which patients first
noted their skin change was 38, which is lower than previous
reports [31].
The age at which predictive genetic testing in adult-onset
disorders should commence has been widely discussed. It is
recommended that individuals should only be tested when
diagnosis would influence their overall management [47]. In the
case of BHDS, genetic testing should therefore be influenced by
the age of commencement of renal screening. Current guidance
for BHDS recommends that renal screening begins at 20 years of
age [3]. A majority of symptomatic adolescents with BHDS present
with pneumothoraces rather than renal cell carcinoma, although
we note that there is a report of an individual younger than 20
developing renal cancer in this disorder [33].
Previous estimates suggest that 5–10% of patients with primary
pneumothoraces have BHDS, yet we observe a mean latency of 6
years between pneumothorax and diagnosis suggesting insuffi-
cient awareness amongst clinicians that will delay instigation of
renal cancer screening. We previously suggested a diagnostic
pathway for patients with pneumothorax by which such a delay
could be avoided [1].
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This systematic review suffers from a number of limitations.
First, all the patient information came from cross-sectional studies.
This can introduce ascertainment bias, although family tracing
would still identify asymptomatic or elderly affected relatives.
Further, due to the lack of patient follow-up, renal cancer, which
tends to present later in life, may be underrepresented and may
contribute to reports of POPVs. This is a limitation inherent in
cross-sectional studies. There has yet to be a prospective analysis
of large BHDS cohorts; this would improve confidence in the
frequencies of phenotypes that develop with age. Second, bias
might have been introduced by the clinical speciality of reporting
authors. We noted that 24.4% of patients were reported by
pulmonologists, 19.0% by dermatologists, 21.8% by nephrologists,
14.8% from genetic departments and the remaining 20% from a
variety of departments including oncology, pathology and general
medicine. However, this variety may act to minimise bias from a
clinician’s specialty. Finally, there was variability in the clinical data
available and the manner by which it had been collected. For
example, only some examinations of the skin were performed by
dermatologists, while CT examinations were available only for a
subset of patients. Nevertheless, systematic analysis of all
published cases is a tractable approach to the analysis of rare
conditions such as BHDS.
In conclusion, this systematic review provides a comprehensive
analysis of the clinical and genetic features of BHDS and is relevant
to respiratory physicians to whom new patients may present with
familial, sporadic and or recurrent pneumothorax. We recommend
that all individuals found to carry a pathogenic FLCN variant be
offered lifelong surveillance for renal cancer, since pneumothorax-
only FLCN variants are likely to be rare.
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